STELARA SQ®
STELARA SQ® (Ustekinumab) is an immunosuppressive drug that reduces inflammation in the body due to various autoimmune diseases.
STELARA SQ® is manufactured by Janssen Biotech.
Administration and Dosage:
For patients with Crohn’s disease, administration of STELARA is a regimen 1 intravenous infusion therapy followed by a maintenance dose of subcutaneous injections every 8 weeks. Patients with Plaque Psoriasis and Psoriatic Arthritis, STELARA is administred subcutaneously at week 1 and then week 4, followed by every 12 weeks regimen.
Indication:
STELARA SQ® is indicated to treat:
- Crohn’s Disease
- Plaque Psoriasis
- Psoriatic Arthritis
Common Side Effects:
The more common side effects of STELARA SQ® include serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.
More information:
Please read the full Prescribing Information and Medication Guide for STELARA SQ® and discuss any questions you have with your doctor.
HAVE QUESTIONS?
